April 2016 Newsletter
Take a look back at the US refractive market in April 1996, when our firm was launched.
Doctors from India discuss their work using the cancer-fighting formulation of aflibercept in the eye.
Meeting has broadened its focus to include many diseases.
One speaker discussed development of an artificial cornea developed using fish scales.
Saunders ruled out taking over as CEO of Valeant, telling Forbes that he would not consider it.
Current CEO J. Michael Pearson is under subpoena to appear April 27 before a US Senate committee investigating drug pricing.
City’s average high in early May is 85 degrees; the low is 67.
This year's agenda includes early European experience with the Abbott Symfony lens, strategies for bringing back LASIK, one-year results for the AcuFocus KAMRA, and new drug delivery platforms for glaucoma drugs.
Please come by anytime or schedule a specific time to meet with someone on our team.
Michael Johnson of Abbott Medical Optics will serve as moderator.
This page is available to everyone for download.
Alcon, the eye care division of Novartis, licensed commercialization of Jetrea outside the US in March 2012.
The NSAID is indicated for preventing pain and treating inflammation postoperatively in cataract patients.
The company also signed an option agreement with YouHealth Eyetech to evaluate lanosterol as a nonsurgical treatment for cataracts.
The new model would pay a 2.5 percent add-on fee plus a flat fee of $16.80 per day.
The Bayh-Dole Act of 1980 gives health officials the authority to suspend exclusivity of a drug developed with the support of federal funding.
The subscription-based service provides time series analysis, benchmarking data, custom graphs that can be downloaded for presentations, and much more.
Nearly 25.5 million IOLs are forecast to be implanted globally in 2016.
• The plant has the capacity to manufacture 3 million IOLs a year, the firm says.
Consumer awareness of corneal inlays has been low.
The group’s concerns include the potential for inaccurate prescriptions; missed diagnosis of serious eye conditions; and creation of a prescription with little meaningful input from an eye doctor.
Intellia, a Massachusetts startup, has filed paperwork for an IPO worth up to $120 million.
Researchers from King's College London tracked a thousand pairs of female twins for 10 years.
A prototype is still five to 10 years away, researchers say.
The recipient was French retina specialist David Sayag, MD, who is helping prototype an OCT angiography module with Heidelberg.
A Swiss team followed 133 eyes in 78 patients who had surgery between 1998 and 2004. After five years, two of every five patients had cataracts.
